DK261490D0 - New pharmaceutical compound - Google Patents

New pharmaceutical compound

Info

Publication number
DK261490D0
DK261490D0 DK261490A DK261490A DK261490D0 DK 261490 D0 DK261490 D0 DK 261490D0 DK 261490 A DK261490 A DK 261490A DK 261490 A DK261490 A DK 261490A DK 261490 D0 DK261490 D0 DK 261490D0
Authority
DK
Denmark
Prior art keywords
pharmaceutical compound
new pharmaceutical
epi
patients
useful
Prior art date
Application number
DK261490A
Other languages
Danish (da)
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to DK261490A priority Critical patent/DK261490D0/da
Publication of DK261490D0 publication Critical patent/DK261490D0/da
Priority to ES91919614T priority patent/ES2083597T3/es
Priority to CZ93786A priority patent/CZ282497B6/cs
Priority to DE69116380T priority patent/DE69116380T2/de
Priority to CA002095356A priority patent/CA2095356A1/en
Priority to RU93032613A priority patent/RU2127600C1/ru
Priority to HU9301253A priority patent/HUT64236A/hu
Priority to AU88711/91A priority patent/AU657926B2/en
Priority to AT91919614T priority patent/ATE132757T1/de
Priority to UA93004415A priority patent/UA35567C2/uk
Priority to JP3518142A priority patent/JPH06502171A/ja
Priority to PCT/DK1991/000317 priority patent/WO1992007584A1/en
Priority to SK428-93A priority patent/SK282516B6/sk
Priority to DK91919614.7T priority patent/DK0558529T3/da
Priority to EP91919614A priority patent/EP0558529B1/de
Priority to GR960400902T priority patent/GR3019514T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK261490A 1990-10-31 1990-10-31 New pharmaceutical compound DK261490D0 (da)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DK261490A DK261490D0 (da) 1990-10-31 1990-10-31 New pharmaceutical compound
EP91919614A EP0558529B1 (de) 1990-10-31 1991-10-18 Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
HU9301253A HUT64236A (en) 1990-10-31 1991-10-18 Process for the production of medical preparatives applicable for the treatment of enlarged time of coagulation
AT91919614T ATE132757T1 (de) 1990-10-31 1991-10-18 Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69116380T DE69116380T2 (de) 1990-10-31 1991-10-18 Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
CA002095356A CA2095356A1 (en) 1990-10-31 1991-10-18 Pharmaceutical preparation for the treatment of prolonged coagulation time
RU93032613A RU2127600C1 (ru) 1990-10-31 1991-10-18 Фармацевтический препарат, обладающий свойством ускорять процесс коагуляции крови, способ ускорения коагуляции крови in vitro и применение ингибитора epi активности в качестве вещества, обладающего свойством ускорять процесс коагуляции крови
ES91919614T ES2083597T3 (es) 1990-10-31 1991-10-18 Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
AU88711/91A AU657926B2 (en) 1990-10-31 1991-10-18 Pharmaceutical preparation for the treatment of prolonged coagulation time
CZ93786A CZ282497B6 (cs) 1990-10-31 1991-10-18 Farmaceutický přípravek k léčbě prodloužené doby koagulace
UA93004415A UA35567C2 (uk) 1990-10-31 1991-10-18 Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
JP3518142A JPH06502171A (ja) 1990-10-31 1991-10-18 長期凝血時間の処置のための薬品製剤
PCT/DK1991/000317 WO1992007584A1 (en) 1990-10-31 1991-10-18 Pharmaceutical preparation for the treatment of prolonged coagulation time
SK428-93A SK282516B6 (sk) 1990-10-31 1991-10-18 Farmaceutický prípravok na liečenie pacientov s predĺženým časom zrážania krvi
DK91919614.7T DK0558529T3 (da) 1990-10-31 1991-10-18 Farmaceutisk præparat til behandling af forlænget koagulationstid
GR960400902T GR3019514T3 (en) 1990-10-31 1996-04-02 Pharmaceutical preparation for the treatment of prolonged coagulation time

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK261490A DK261490D0 (da) 1990-10-31 1990-10-31 New pharmaceutical compound

Publications (1)

Publication Number Publication Date
DK261490D0 true DK261490D0 (da) 1990-10-31

Family

ID=8113744

Family Applications (2)

Application Number Title Priority Date Filing Date
DK261490A DK261490D0 (da) 1990-10-31 1990-10-31 New pharmaceutical compound
DK91919614.7T DK0558529T3 (da) 1990-10-31 1991-10-18 Farmaceutisk præparat til behandling af forlænget koagulationstid

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK91919614.7T DK0558529T3 (da) 1990-10-31 1991-10-18 Farmaceutisk præparat til behandling af forlænget koagulationstid

Country Status (15)

Country Link
EP (1) EP0558529B1 (de)
JP (1) JPH06502171A (de)
AT (1) ATE132757T1 (de)
AU (1) AU657926B2 (de)
CA (1) CA2095356A1 (de)
CZ (1) CZ282497B6 (de)
DE (1) DE69116380T2 (de)
DK (2) DK261490D0 (de)
ES (1) ES2083597T3 (de)
GR (1) GR3019514T3 (de)
HU (1) HUT64236A (de)
RU (1) RU2127600C1 (de)
SK (1) SK282516B6 (de)
UA (1) UA35567C2 (de)
WO (1) WO1992007584A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
AU636080B1 (en) * 1992-07-21 1993-04-08 Profy International Corporation Unitary loose sheet binder
RU2195676C2 (ru) * 1999-08-26 2002-12-27 Уральская государственная медицинская академия Способ комплексной оценки прогноза эффективности лечения диффузных заболеваний соединительной ткани низкомолекулярными антикоагулянтами
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1282438B1 (de) * 2000-05-10 2005-08-03 Novo Nordisk Health Care AG Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen
IL161407A0 (en) 2001-10-15 2004-09-27 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
EP1919499A2 (de) * 2005-07-29 2008-05-14 Universiteit van Maastricht Regulierung von gewebefaktoraktivität durch proteine und tfpi (tissue factor pathway inhibitor)
RU2011101969A (ru) 2008-06-30 2012-08-10 Ново Нордиск А/С (DK) Антитела к человеческому интерлейкину-20
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CA2747721C (en) 2008-12-19 2021-07-20 Baxter International Inc. Tfpi inhibitors and methods of use
CN102325795B (zh) 2008-12-22 2015-03-25 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂的抗体
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
EP3409289B1 (de) * 2010-02-26 2020-09-30 Novo Nordisk A/S Stabile, antikörperhaltige zusammensetzungen
RS59830B1 (sr) 2010-03-01 2020-02-28 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
EP2547355B1 (de) 2010-03-19 2017-01-11 Baxalta GmbH Tfpi-hemmer und verwendungsverfahren dafür
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
US9260518B2 (en) 2010-06-30 2016-02-16 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
EP2827883B1 (de) 2012-03-21 2019-05-08 Baxalta GmbH Tfpi inhibitoren und deren verwendung
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359463A (en) * 1980-11-26 1982-11-16 Rock Gail A Stabilization of Factor VIII activity in whole blood or blood plasma
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
IL87171A (en) * 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
AU617795B2 (en) 1988-03-17 1991-12-05 Leukotech A/S Heparin-binding proteins, dna coding for them, processes for producing them as well as therapeutic preparations containing them
DK148890D0 (da) * 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat

Also Published As

Publication number Publication date
SK42893A3 (en) 1993-09-08
AU657926B2 (en) 1995-03-30
CA2095356A1 (en) 1992-05-01
UA35567C2 (uk) 2001-04-16
ATE132757T1 (de) 1996-01-15
WO1992007584A1 (en) 1992-05-14
EP0558529B1 (de) 1996-01-10
DE69116380T2 (de) 1996-07-11
AU8871191A (en) 1992-05-26
EP0558529A1 (de) 1993-09-08
HUT64236A (en) 1993-12-28
ES2083597T3 (es) 1996-04-16
JPH06502171A (ja) 1994-03-10
DE69116380D1 (de) 1996-02-22
CZ78693A3 (en) 1993-12-15
HU9301253D0 (en) 1993-07-28
CZ282497B6 (cs) 1997-07-16
RU2127600C1 (ru) 1999-03-20
DK0558529T3 (da) 1996-06-03
GR3019514T3 (en) 1996-07-31
SK282516B6 (sk) 2002-10-08

Similar Documents

Publication Publication Date Title
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
KR920019342A (ko) 골질환 치료제
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
FI946004A0 (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
DE59010810D1 (de) Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
ES2044840T3 (es) Composiciones estabilizadas del activador del plasminogeno de tejido humano.
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
ES2058651T3 (es) Uso derivados de guanidina para la fabricacion de un medicamento con actividad antagonista de npy.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DE68903092D1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
NO890046L (no) Disubstituerte pyridiner.
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
DE58903964D1 (de) Fluessige orale formulierung.
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
HK17880A (en) N-(1'-allyl-2'-pyrrolidylmethyl)-2,3-dimethoxy-5-sulphamoylbenzamide and derivatives
DE59106803D1 (de) Substituierte Pyrido-oxazine.
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
DK392288A (da) Human monoklonale antistoffer samt profylaktiske og terapeutiske midler mod infrektioese sygdomme, der indeholder samme som aktiv bestanddel
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
DK0669826T3 (da) (-)-Metrifonatholdigt lægemiddel

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment